文献速递质量管理与危急值临床生化临床免疫

可溯源时代下体外诊断医疗器械与医学实验室性能监测的质量控制再设计

Redesigning the surveillance of in vitro diagnostic medical devices and of medical laboratory performance by quality control in the traceability era.
PubMed 文献 · Clin Chem Lab Med · 2022-12-22

本文讨论在可溯源时代,体外诊断医疗器械(IVD-MD)制造商应提供具有无偏靶值和可接受范围的质量控制(QC)材料,用于内部QC(IQC)组件I的溯源验证与对齐监测。医学实验室应通过IQC组件II改进IQC过程及其判断标准,将性能(以测量不确定度MU估计)与分析性能规范(APS)直接关联,并在性能恶化时采取纠正措施。同时,参与符合特定计量学标准的外部质量评估(EQA)项目对评估IVD-MD和医学实验室性能至关重要。

要点

  • IVD制造商应提供用于IQC组件I的QC材料,其靶值无偏且可接受范围对应临床样本的APS。
  • 医学实验室应通过IQC组件II将性能(以MU估计)与APS直接关联,性能恶化时采取纠正措施。
  • 参与符合计量学标准的EQA项目对评估IVD-MD和实验室性能的协调性与临床适用性至关重要。

核心结论

  • IVD制造商应提供用于IQC组件I的QC材料,其靶值无偏且可接受范围对应临床样本的APS。
  • 医学实验室应通过IQC组件II将性能(以MU估计)与APS直接关联,并在性能恶化时采取纠正措施。
  • 参与符合特定计量学标准的EQA项目对评估IVD-MD和医学实验室性能至关重要。

主要发现

  • IVD制造商对上市IVD-MD的溯源性负有全部责任,包括提供作为测量系统一部分的QC材料。
  • IQC组件I所用QC材料应具有无偏靶值和可接受范围,对应临床样本的APS。
  • IQC组件II应改进IQC过程及判断标准,将性能(以MU估计)与APS直接关联。
  • 符合计量学标准的EQA需使用可交换材料、以参考程序赋值并定义和应用最大允许APS。

关键数值与推荐

  • IQC组件I的QC材料应具有无偏靶值和可接受范围,对应临床样本的APS。
  • IQC组件II应将性能(以MU估计)与APS直接关联。
  • EQA项目应使用可交换材料、以参考程序赋值并定义和应用最大允许APS。

临床怎么用

  • IVD制造商应提供用于IQC组件I的QC材料,以支持终端用户日常实践中的溯源验证与对齐监测。
  • 医学实验室应改进IQC过程及判断标准,将性能(以MU估计)与APS直接关联,性能恶化时采取纠正措施。
  • 医学实验室应参与符合特定计量学标准的EQA项目,以评估测量结果的协调性与临床适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IVD manufacturers have total responsibility in terms of the traceability of marketed in vitro diagnostic medical devices (IVD-MD). This includes the provision of a quality control (QC) material as a part of the measuring system, suitable for traceability verification and alignment surveillance by end-users in daily practice. This material [to be used for the internal QC (IQC) component I as described in this paper] should have unbiased target values and an acceptability range corresponding to analytical performance specifications (APS) for suitable (expanded) measurement uncertainty (MU) on clinical samples. On the other hand, medical laboratories (by the IQC component II as described in this paper) should improve the IQC process and its judging criteria to establish a direct link between their performance, estimated as MU of provided results, and APS defined according to recommended models to apply corrective actions if the performance is worsening with the risk to jeopardize the clinical validity of test results. The participation to external quality assessment (EQA) programs that meet specific metrological criteria is also central to the evaluation of performance of IVD-MDs and of medical laboratories in terms of harmonization and clinical suitability of their measurements. In addition to the use of commutable materials, in this type of EQA it is necessary to assign values to them with selected reference procedures and to define and apply maximum allowable APS to substantiate the suitability of laboratory measurements in the clinical setting.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Panteghini M. Redesigning the surveillance of in vitro diagnostic medical devices and of medical laboratory performance by quality control in the traceability era. Clin Chem Lab Med. 2022. PMID: 36542481. doi:10.1515/cclm-2022-1257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。